Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.
Robyn KendallAlan A MartinDhvani ShahSoham ShuklaChris ComptonAfisi S IsmailaPublished in: International journal of chronic obstructive pulmonary disease (2023)
FF/UMEC/VI offers greater clinical benefits and is a cost-effective treatment option compared with TIO for the treatment of adult patients with COPD with persistent symptoms and/or who are at risk of exacerbation in the UK.